Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ)

4.8800
-0.2600
(-5.06%)
At close: April 30 at 3:04:42 PM GMT+8
Loading Chart for 000908.SZ
  • Previous Close 5.1400
  • Open 5.4800
  • Bid --
  • Ask 5.1400 x --
  • Day's Range 5.1400 - 5.5500
  • 52 Week Range 0.7200 - 6.3600
  • Volume 5,515,800
  • Avg. Volume 22,095,043
  • Market Cap (intraday) 4.293B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 30.50
  • EPS (TTM) 0.1600
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Aug 23, 2018
  • 1y Target Est --

Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmology and API products, as well as engages in the research and development of anti-tumor, cancer, and cardiovascular drugs; and provides skin care products. In addition, the company provides CDMO/CMO services. The company was founded in 2003 and is headquartered in Shanghai, China.

www.jfzhiyao.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 000908.SZ

View More

Performance Overview: 000908.SZ

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

000908.SZ
0.20%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

000908.SZ
188.76%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

000908.SZ
53.94%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

000908.SZ
17.59%
SSE Composite Index (000001.SS)
14.65%

Compare To: 000908.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 000908.SZ

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    4.29B

  • Enterprise Value

    4.69B

  • Trailing P/E

    30.33

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.38

  • Price/Book (mrq)

    61.42

  • Enterprise Value/Revenue

    11.27

  • Enterprise Value/EBITDA

    24.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    36.61%

  • Return on Assets (ttm)

    -0.21%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    416.03M

  • Net Income Avi to Common (ttm)

    152.3M

  • Diluted EPS (ttm)

    0.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    85.52M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.67M

Research Analysis: 000908.SZ

View More

Company Insights: 000908.SZ

Research Reports: 000908.SZ

View More

People Also Watch